Skip to main content
Clinical Trials/JPRN-jRCT1080222785
JPRN-jRCT1080222785
Completed
Phase 3

An exploratory study of treatment sensitivity and prognostic factors in a Phase III, randomized, controlled study comparing the efficacy and safety of mFOLFOX6 + bevacizumab therapy vs. mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naive wild-type RAS(KRAS/NRAS) unresectable advanced or recurrent colorectal cancer

Takeda Pharmaceutical Company Limited0 sites757 target enrollmentMarch 6, 2015

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Colorectal cancer
Sponsor
Takeda Pharmaceutical Company Limited
Enrollment
757
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 6, 2015
End Date
March 31, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients who are enrolled in the main study and personally provided written consent after adequately explained about the contents of the additional study

Exclusion Criteria

  • Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study

Outcomes

Primary Outcomes

Not specified

Similar Trials